Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 2:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,837 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Merck Sharp & Dohme LLC Clear all
Completed No phase listed Observational Accepts healthy volunteers

Early Childhood Obesity Programming by Intrauterine Growth Restriction

NCT03402139
View directory record Official record
Conditions
Childhood Obesity, Epigenetics
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
1 Hour to 24 Months
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 4, 2026, 2:59 AM EDT
Active, not recruiting Early Phase 1 Interventional

Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors

NCT03832569
View directory record Official record
Conditions
Solid Tumors, Identified by NGS, PCR or IHC
Interventions
Pembrolizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 4, 2026, 2:59 AM EDT
Completed Phase 2 Interventional

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

NCT04123366
View directory record Official record
Conditions
Solid Tumors
Interventions
Olaparib, Pembrolizumab
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
21
States / cities
Birmingham, Alabama • Gilbert, Arizona • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 4, 2026, 2:59 AM EDT
Completed Phase 3 Interventional Results available

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

NCT03675737
View directory record Official record
Conditions
Stomach Neoplasms
Interventions
Pembrolizumab, Cisplatin, 5-fluorouracil, oxaliplatin, capecitabine, Placebo for Pembrolizumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
10
States / cities
Los Angeles, California • Orange, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 4, 2026, 2:59 AM EDT
Completed Phase 1 Interventional Results available

Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas

NCT02313272
View directory record Official record
Conditions
Malignant Glioma
Interventions
Hypofractionated Stereotactic Irradiation (HFSRT), Pembrolizumab, Bevacizumab
Radiation · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 4, 2026, 2:59 AM EDT
Terminated Phase 1 Interventional

Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00744354
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
bortezomib, pegylated liposomal doxorubicin hydrochloride, vorinostat
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
4
States / cities
New York, New York • Chapel Hill, North Carolina • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 4, 2026, 2:59 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer

NCT03182894
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Epacadostat (INCB024360) in Combination with Pembrolizumab (MK-3475) and Azacitidine (VIDAZA)
Drug
Lead sponsor
James J Lee
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 4, 2026, 2:59 AM EDT
Completed No phase listed Observational

Study on Immunopathogenesis in HIV and Hepatitis C Coinfection

NCT01296529
View directory record Official record
Conditions
HIV Infection, Hepatitis C Infection, Fibrosis, Inflammation
Interventions
Not listed
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 12, 2012 · Synced Oct 4, 2026, 2:59 AM EDT
Withdrawn Phase 1 Interventional

Pembrolizumab + Defactinib In Pleural Mesothelioma

NCT04201145
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
Pembrolizumab, Defactinib
Drug
Lead sponsor
Raphael Bueno, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 4, 2026, 2:59 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)

NCT03969901
View directory record Official record
Conditions
Suspected or Documented Gram-negative Bacterial Infection
Interventions
IMI/REL, Active Control, Oral Switch
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
Up to 17 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
8
States / cities
Tucson, Arizona • Long Beach, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 4, 2026, 2:59 AM EDT
Completed No phase listed Observational

Correlation of Calcitonin Gene-Related Peptide (CGRP) Levels in Saliva With the Evolution of an Attack of Migraine

NCT00772473
View directory record Official record
Conditions
Headache, Migraine
Interventions
subjects personal triptan
Other
Lead sponsor
Clinvest
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated May 25, 2009 · Synced Oct 4, 2026, 2:59 AM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)

NCT03990961
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, Lymphoma
Interventions
Pembrolizumab
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 4, 2026, 2:59 AM EDT
Not listed No phase listed Observational

Hepatitis C (HCV) Cure and Kidney Health

NCT03407703
View directory record Official record
Conditions
Hepatitis C
Interventions
Elbasvir / Grazoprevir Oral Tablet [Zepatier]
Drug
Lead sponsor
San Francisco Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 4, 2026, 2:59 AM EDT
Completed Phase 3 Interventional Results available

HALT Progression of Polycystic Kidney Disease Study B

NCT01885559
View directory record Official record
Conditions
Kidney, Polycystic
Interventions
Lisinopril, Telmisartan, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
15 Years to 64 Years
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
7
States / cities
Aurora, Colorado • Atlanta, Georgia • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Oct 4, 2026, 2:59 AM EDT
Completed Phase 1 Interventional

Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer

NCT02437370
View directory record Official record
Conditions
Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Recurrent Bladder Carcinoma, Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter, Regional Urothelial Carcinoma of the Renal Pelvis and Ureter, Stage III Bladder Urothelial Carcinoma, Stage III Urethral Cancer, Stage IV Bladder Urothelial Carcinoma, Stage IV Urethral Cancer, Urethral Urothelial Carcinoma
Interventions
Pembrolizumab, Docetaxel, Gemcitabine Hydrochloride
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 4, 2026, 2:59 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

NCT05929235
View directory record Official record
Conditions
Advanced Urothelial Carcinoma, Oral Drug Administration, Open Label
Interventions
FX-909, Pembrolizumab (KEYTRUDA ®), KEYTRUDA ®( Pembrolizumab)
Drug
Lead sponsor
Flare Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
12
States / cities
San Francisco, California • New Haven, Connecticut • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 4, 2026, 2:59 AM EDT
Completed Phase 4 Interventional Results available

Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?

NCT01101750
View directory record Official record
Conditions
Cervical Cancer, Hpv, Warts
Interventions
Quadrivalent HPV for types 6, 11, 16 and 18
Biological
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
9 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 4, 2026, 2:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial to Compare Forms of MK-1167 in Healthy People (MK-1167-011)

NCT07334860
View directory record Official record
Conditions
Healthy
Interventions
MK-1167
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 4, 2026, 2:59 AM EDT
Completed Phase 4 Interventional Results available

Drug and Non-Drug Treatment Of Severe Migraine

NCT00910689
View directory record Official record
Conditions
Migraine Headache
Interventions
Propranolol or nadolol, Placebo control, Behavioral Migraine Management (BMM), Optimal Acute Therapy
Drug · Behavioral
Lead sponsor
Ohio University
Other
Eligibility
18 Years to 65 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Athens, Ohio • Westerville, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 4, 2026, 2:59 AM EDT
Completed Phase 1 Interventional Results available

A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)

NCT02179918
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
PF-05082566, MK-3475
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
9
States / cities
Los Angeles, California • New Haven, Connecticut • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 4, 2026, 2:59 AM EDT
Recruiting Phase 1 Interventional

A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

NCT07247110
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
MK-4716, Pembrolizumab, Cetuximab
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
New Brunswick, New Jersey • Irving, Texas • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 4, 2026, 2:59 AM EDT
Terminated Phase 1Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)

NCT03598608
View directory record Official record
Conditions
Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell
Interventions
pembrolizumab, Favezelimab
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
8
States / cities
Gilbert, Arizona • Duarte, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 4, 2026, 2:59 AM EDT
Recruiting Phase 2 Interventional

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

NCT04701476
View directory record Official record
Conditions
Colorectal Cancer; Lung Cancer
Interventions
TATE and pembrolizumab, TAS-102 pill, Regorafenib Pill
Drug
Lead sponsor
Teclison Ltd.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 4, 2026, 2:59 AM EDT
Not listed No phase listed Observational

Effect of Montelukast on Basophils, In-vitro

NCT00710450
View directory record Official record
Conditions
Allergic Asthma, Allergic Rhinitis
Interventions
Not listed
Lead sponsor
Creighton University
Other
Eligibility
12 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 23, 2011 · Synced Oct 4, 2026, 2:59 AM EDT